David Hadley, Mediclinic Middle East CEO, will briefly present an overview of the division focusing on the following key areas:
− Mediclinic’s position as a leading private healthcare provider in the UAE
− Attractive long-term market fundamentals in the UAE
− Delivery of superior international standards in patient experience and clinical excellence
− Expansion opportunities and sustainable long-term growth
− Future plans across the continuum of care
Guidance for Mediclinic Middle East remains unchanged. The division expects to deliver FY19 revenue growth (adjusted for the adoption of IFRS 15) in the high single-digit percentage range reflecting the underlying operating performance of the business and additional bed capacity coming online in the second half of the year. The operating leverage in the underlying business, offset to some extent by the start-up losses associated with expansion projects, is expected to deliver a slightly improved EBITDA margin compared to the prior year (adjusted for the adoption of IFRS 15, FY18: 13.0%). The Group continues to expect ongoing EBITDA margin expansion to around 20% by FY23 given the ongoing improvements and expansion opportunities across the region.
No new material information will be provided during the event. Presentation material will be made available online shortly after 7am GMT, here: https://ir.mediclinic.com/resultscentre/presentations-and-investor-days.